Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era

Naresh V. Desireddi, Kimberly A. Roehl, Stacy Loeb, Xiaoying Yu, Christopher R. Griffin, Shilajit D Kundu, Misop Han, William J Catalona*

*Corresponding author for this work

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objectives: Since the initiation of prostate-specific antigen (PSA) screening, the progression-free survival (PFS) rates after radical prostatectomy have markedly improved. However, few studies have evaluated whether PFS has improved for stage and grade-matched patients. Our objective was to examine differences in PFS after radical prostatectomy between the pre-PSA era (before 1992) and the PSA era, controlling for tumor stage and grade. Methods: From 1983 to 2003, 3456 men underwent radical prostatectomy by one surgeon. The 10-year PFS rates were calculated for each era and stratified by pathologic tumor stage and grade. Kaplan-Meier curves were generated to show biochemical PFS over time. Results: The proportion of patients with pathologically organ-confined disease increased from 64% to 69%, consistent with stage migration. The PFS rate in the PSA era was 87%, 63%, 58%, and 31% versus 71%, 63%, 47%, and 19% in the pre-PSA era for Stage pT2R0, pT3R0, pT2-T3R1, and pT3c/N1 disease, respectively. The PFS rate stratified by Gleason grade in the PSA era was 84%, 63%, and 37% versus 66%, 49%, and 32% in the pre-PSA era for Gleason grade less than 7, 7, and 8 to 10, respectively. The 10-year PFS rate for organ-confined disease improved from 70% in the pre-PSA era to 86% in the PSA era. Conclusions: Patients treated with radical prostatectomy in the PSA era have improved survival outcomes when controlling for pathologic stage and grade. This is likely attributed to the earlier detection of cancer through PSA screening, better identification of patients amenable to curative therapy, and the effects of lead-time bias.

Original languageEnglish (US)
Pages (from-to)950-955
Number of pages6
JournalUrology
Volume70
Issue number5
DOIs
StatePublished - Nov 1 2007

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Disease-Free Survival
Survival Rate
Early Detection of Cancer
Neoplasms
Prostatic Neoplasms
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Desireddi, Naresh V. ; Roehl, Kimberly A. ; Loeb, Stacy ; Yu, Xiaoying ; Griffin, Christopher R. ; Kundu, Shilajit D ; Han, Misop ; Catalona, William J. / Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era. In: Urology. 2007 ; Vol. 70, No. 5. pp. 950-955.
@article{14f6545fd4b746c19a4e1e7b8b09d40f,
title = "Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era",
abstract = "Objectives: Since the initiation of prostate-specific antigen (PSA) screening, the progression-free survival (PFS) rates after radical prostatectomy have markedly improved. However, few studies have evaluated whether PFS has improved for stage and grade-matched patients. Our objective was to examine differences in PFS after radical prostatectomy between the pre-PSA era (before 1992) and the PSA era, controlling for tumor stage and grade. Methods: From 1983 to 2003, 3456 men underwent radical prostatectomy by one surgeon. The 10-year PFS rates were calculated for each era and stratified by pathologic tumor stage and grade. Kaplan-Meier curves were generated to show biochemical PFS over time. Results: The proportion of patients with pathologically organ-confined disease increased from 64{\%} to 69{\%}, consistent with stage migration. The PFS rate in the PSA era was 87{\%}, 63{\%}, 58{\%}, and 31{\%} versus 71{\%}, 63{\%}, 47{\%}, and 19{\%} in the pre-PSA era for Stage pT2R0, pT3R0, pT2-T3R1, and pT3c/N1 disease, respectively. The PFS rate stratified by Gleason grade in the PSA era was 84{\%}, 63{\%}, and 37{\%} versus 66{\%}, 49{\%}, and 32{\%} in the pre-PSA era for Gleason grade less than 7, 7, and 8 to 10, respectively. The 10-year PFS rate for organ-confined disease improved from 70{\%} in the pre-PSA era to 86{\%} in the PSA era. Conclusions: Patients treated with radical prostatectomy in the PSA era have improved survival outcomes when controlling for pathologic stage and grade. This is likely attributed to the earlier detection of cancer through PSA screening, better identification of patients amenable to curative therapy, and the effects of lead-time bias.",
author = "Desireddi, {Naresh V.} and Roehl, {Kimberly A.} and Stacy Loeb and Xiaoying Yu and Griffin, {Christopher R.} and Kundu, {Shilajit D} and Misop Han and Catalona, {William J}",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.urology.2007.06.1119",
language = "English (US)",
volume = "70",
pages = "950--955",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era. / Desireddi, Naresh V.; Roehl, Kimberly A.; Loeb, Stacy; Yu, Xiaoying; Griffin, Christopher R.; Kundu, Shilajit D; Han, Misop; Catalona, William J.

In: Urology, Vol. 70, No. 5, 01.11.2007, p. 950-955.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era

AU - Desireddi, Naresh V.

AU - Roehl, Kimberly A.

AU - Loeb, Stacy

AU - Yu, Xiaoying

AU - Griffin, Christopher R.

AU - Kundu, Shilajit D

AU - Han, Misop

AU - Catalona, William J

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Objectives: Since the initiation of prostate-specific antigen (PSA) screening, the progression-free survival (PFS) rates after radical prostatectomy have markedly improved. However, few studies have evaluated whether PFS has improved for stage and grade-matched patients. Our objective was to examine differences in PFS after radical prostatectomy between the pre-PSA era (before 1992) and the PSA era, controlling for tumor stage and grade. Methods: From 1983 to 2003, 3456 men underwent radical prostatectomy by one surgeon. The 10-year PFS rates were calculated for each era and stratified by pathologic tumor stage and grade. Kaplan-Meier curves were generated to show biochemical PFS over time. Results: The proportion of patients with pathologically organ-confined disease increased from 64% to 69%, consistent with stage migration. The PFS rate in the PSA era was 87%, 63%, 58%, and 31% versus 71%, 63%, 47%, and 19% in the pre-PSA era for Stage pT2R0, pT3R0, pT2-T3R1, and pT3c/N1 disease, respectively. The PFS rate stratified by Gleason grade in the PSA era was 84%, 63%, and 37% versus 66%, 49%, and 32% in the pre-PSA era for Gleason grade less than 7, 7, and 8 to 10, respectively. The 10-year PFS rate for organ-confined disease improved from 70% in the pre-PSA era to 86% in the PSA era. Conclusions: Patients treated with radical prostatectomy in the PSA era have improved survival outcomes when controlling for pathologic stage and grade. This is likely attributed to the earlier detection of cancer through PSA screening, better identification of patients amenable to curative therapy, and the effects of lead-time bias.

AB - Objectives: Since the initiation of prostate-specific antigen (PSA) screening, the progression-free survival (PFS) rates after radical prostatectomy have markedly improved. However, few studies have evaluated whether PFS has improved for stage and grade-matched patients. Our objective was to examine differences in PFS after radical prostatectomy between the pre-PSA era (before 1992) and the PSA era, controlling for tumor stage and grade. Methods: From 1983 to 2003, 3456 men underwent radical prostatectomy by one surgeon. The 10-year PFS rates were calculated for each era and stratified by pathologic tumor stage and grade. Kaplan-Meier curves were generated to show biochemical PFS over time. Results: The proportion of patients with pathologically organ-confined disease increased from 64% to 69%, consistent with stage migration. The PFS rate in the PSA era was 87%, 63%, 58%, and 31% versus 71%, 63%, 47%, and 19% in the pre-PSA era for Stage pT2R0, pT3R0, pT2-T3R1, and pT3c/N1 disease, respectively. The PFS rate stratified by Gleason grade in the PSA era was 84%, 63%, and 37% versus 66%, 49%, and 32% in the pre-PSA era for Gleason grade less than 7, 7, and 8 to 10, respectively. The 10-year PFS rate for organ-confined disease improved from 70% in the pre-PSA era to 86% in the PSA era. Conclusions: Patients treated with radical prostatectomy in the PSA era have improved survival outcomes when controlling for pathologic stage and grade. This is likely attributed to the earlier detection of cancer through PSA screening, better identification of patients amenable to curative therapy, and the effects of lead-time bias.

UR - http://www.scopus.com/inward/record.url?scp=36549046578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549046578&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.06.1119

DO - 10.1016/j.urology.2007.06.1119

M3 - Article

VL - 70

SP - 950

EP - 955

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -